Downtown UAQ | Sobha Realty Sells Over 50% of Launch Inventory Within First Week
3.10.2025 08:00:00 CEST | Business Wire | Press Release
Sobha Realty has announced strong initial sales at its flagship Downtown UAQ | Sobha Realty master development, reinforcing rising investor confidence in Umm Al Quwain as the UAE’s next coastal growth hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002867954/en/
Downtown UAQ | Sobha Realty (Photo: AETOSWire)
Within just one week of its launch, the developer confirmed that over 50% of units in the first three residential towers were sold, setting a new benchmark for sales velocity in the northern emirates.
The 25-million-square-foot master development, located along Umm Al Quwain’s natural waterfront, is envisioned as the Coastal Skyline of the Future. The project integrates premium residences, commercial hubs, hospitality offerings, and lifestyle amenities to create an exceptional living experience. It is designed to balance modern living with environmental stewardship, with more than half of the total land area dedicated to open and green spaces.
The master plan spans 11 kilometers of pristine waterfront and includes over 7 kilometers of uninterrupted natural beach, two marinas, landscaped boulevards, and future-ready mobility solutions such as water taxis. It will also feature the UAQ Trade Centre, premium office space, and leisure attractions to strengthen its position as a mixed-use destination.
The first residential cluster, Sobha Aquamont, was unveiled earlier this year and comprises three towers of one-, two-, and three-bedroom waterfront apartments. The towers are designed to maximize natural light and coastal views, in line with Sobha Realty’s emphasis on luxury, craftsmanship, and sustainability.
“Umm Al Quwain is emerging as a highly attractive destination for residents and investors seeking world-class coastal living in a natural environment,” said Francis Alfred, Managing Director of Sobha Realty. “The strong sales response at Downtown UAQ reflects both the confidence in Sobha Realty’s vision and the growing appeal of Umm Al Quwain as a market poised for long-term growth.”
Adding to Sobha Realty’s expanding UAE portfolio of luxury communities, Downtown UAQ | Sobha Realty reinforces the company’s reputation for engineering excellence and sustainable urban design. It also highlights the growing momentum of mixed-use coastal projects in the UAE, which are attracting increasing interest from both domestic buyers and international investors.
By setting a new sales benchmark in its opening week, Downtown UAQ | Sobha Realty has established itself as one of the region’s most ambitious and promising waterfront destinations.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20251002867954/en/
Contacts
Pritha Chatterjee - Head - PR and Corporate Communications at Sobha Realty
pritha.chatterjee@sobharealty.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom